Shanghai Fosun Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate
Shanghai Fosun Pharmaceutical Group Co Ltd cash flow reinvestment rate. Shanghai Fosun Pharmaceutical Group Co Ltd (600196) has a Cash Flow Reinvestment Rate of 0.85x as of December 2025, reinvesting CN¥2.03 Billion (capex CN¥1.28 Billion plus investments CN¥753.03 Million) from operating cash flow of CN¥2.40 Billion. See financial flexibility index of Shanghai Fosun Pharmaceutical Group Co L to measure the company's free cash flow as a share of total liabilities.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Shanghai Fosun Pharmaceutical Group Co Ltd (1998–2025)
Cash flow reinvestment rate of Shanghai Fosun Pharmaceutical Group Co Ltd from 1998 to 2025. Historical reinvestment intensity for Shanghai Fosun Pharmaceutical Group Co Ltd across 28 annual periods. Explore Shanghai Fosun Pharmaceutical Group Co L cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Shanghai Fosun Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate by Year (1998–2025)
Shanghai Fosun Pharmaceutical Group Co Ltd cash flow reinvestment rate by year from 1998 to 2025. Year-by-year capital reinvestment analysis for Shanghai Fosun Pharmaceutical Group Co Ltd. For the full cash flow conversion analysis, see cash efficiency ratio of Shanghai Fosun Pharmaceutical Group Co L.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.12x | CN¥6.75 Billion | CN¥6.01 Billion | CN¥4.45 Billion | ▼ -0.5% |
| 2024 | 1.13x | CN¥5.06 Billion | CN¥4.48 Billion | CN¥4.41 Billion | ▼ -46.1% |
| 2023 | 2.10x | CN¥9.16 Billion | CN¥4.36 Billion | CN¥5.34 Billion | ▼ -0.7% |
| 2022 | 2.11x | CN¥8.91 Billion | CN¥4.22 Billion | CN¥5.89 Billion | ▲ +60.9% |
| 2021 | 1.31x | CN¥5.19 Billion | CN¥3.95 Billion | CN¥4.97 Billion | ▼ -34.1% |
| 2020 | 1.99x | CN¥5.14 Billion | CN¥2.58 Billion | CN¥4.44 Billion | ▼ -20.8% |
| 2019 | 2.52x | CN¥8.11 Billion | CN¥3.22 Billion | CN¥3.96 Billion | ▲ +42.6% |
| 2018 | 1.76x | CN¥5.21 Billion | CN¥2.95 Billion | CN¥3.17 Billion | ▲ +34.4% |
| 2017 | 1.31x | CN¥3.39 Billion | CN¥2.58 Billion | CN¥2.17 Billion | ▼ -36.6% |
| 2016 | 2.07x | CN¥4.37 Billion | CN¥2.11 Billion | CN¥1.92 Billion | ▲ +41.5% |
| 2015 | 1.46x | CN¥2.37 Billion | CN¥1.62 Billion | CN¥1.24 Billion | ▲ +56.9% |
| 2014 | 0.93x | CN¥1.12 Billion | CN¥1.20 Billion | CN¥1.12 Billion | ▼ -9.3% |
| 2013 | 1.03x | CN¥1.04 Billion | CN¥1.01 Billion | CN¥1.04 Billion | ▼ -41.0% |
| 2012 | 1.74x | CN¥1.16 Billion | CN¥665.52 Million | CN¥1.16 Billion | ▼ -30.7% |
| 2011 | 2.52x | CN¥796.83 Million | CN¥316.65 Million | CN¥796.83 Million | ▲ +50.9% |
| 2010 | 1.67x | CN¥339.17 Million | CN¥203.36 Million | CN¥339.17 Million | ▲ +25.5% |
| 2009 | 1.33x | CN¥348.07 Million | CN¥261.87 Million | CN¥348.07 Million | ▲ +47.1% |
| 2008 | 0.90x | CN¥210.63 Million | CN¥233.04 Million | CN¥210.63 Million | ▼ -43.3% |
| 2007 | 1.59x | CN¥209.71 Million | CN¥131.48 Million | CN¥209.71 Million | ▲ +10.6% |
| 2006 | 1.44x | CN¥266.61 Million | CN¥184.91 Million | CN¥266.61 Million | ▲ +22.0% |
| 2005 | 1.18x | CN¥222.60 Million | CN¥188.35 Million | CN¥222.60 Million | ▲ +18.2% |
| 2004 | 1.00x | CN¥205.02 Million | CN¥205.10 Million | CN¥205.02 Million | ▼ -43.2% |
| 2003 | 1.76x | CN¥264.05 Million | CN¥150.14 Million | CN¥264.05 Million | ▲ +29.2% |
| 2002 | 1.36x | CN¥139.52 Million | CN¥102.47 Million | CN¥139.52 Million | ▼ -34.4% |
| 2001 | 2.08x | CN¥141.51 Million | CN¥68.15 Million | CN¥141.51 Million | ▲ +127.0% |
| 2000 | 0.91x | CN¥126.63 Million | CN¥138.43 Million | CN¥126.63 Million | ▼ -55.2% |
| 1999 | 2.04x | CN¥77.99 Million | CN¥38.20 Million | CN¥77.99 Million | ▲ +160.1% |
| 1998 | 0.79x | CN¥52.25 Million | CN¥66.55 Million | CN¥52.25 Million | — |